# Xenon Pharmaceuticals Inc. clinical trials: 23 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials with Xenon Pharmaceuticals Inc. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Xenon Pharmaceuticals Inc.: 23 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/xenon-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 20, 2025 | NCT07217860 | An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) | Xenon Pharmaceuticals Inc. | Phase 3 | Active not recruiting | Bipolar Depression, Bipolar I Disorder, Bipolar Disorder, Bipolar II Disorder | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07217860) |
| September 15, 2025 | NCT07172516 | A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) | Xenon Pharmaceuticals Inc. | Phase 3 | Active not recruiting | Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07172516) |
| July 22, 2025 | NCT07076407 | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | Xenon Pharmaceuticals Inc. | Phase 3 | Active not recruiting | Major Depressive Disorder | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07076407) |
| April 10, 2025 | NCT06922110 | An Open-Label Study of Azetukalner in Major Depressive Disorder | Xenon Pharmaceuticals Inc. | Phase 3 | Active not recruiting | Major Depressive Disorder | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06922110) |
| January 15, 2025 | NCT06775379 | A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | Xenon Pharmaceuticals Inc. | Phase 3 | Terminated | Major Depressive Disorder | 357 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06775379) |
| February 8, 2023 | NCT05718817 | An Open-label Study of XEN1101 in Epilepsy | Xenon Pharmaceuticals Inc. | Phase 3 | Enrolling by invitation | Focal Epilepsy, Tonic-Clonic Seizures | 880 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05718817) |
| February 8, 2023 | NCT05716100 | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) | Xenon Pharmaceuticals Inc. | Phase 3 | Recruiting | Focal Onset Seizures | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05716100) |
| December 28, 2022 | NCT05667142 | A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures | Xenon Pharmaceuticals Inc. | Phase 3 | Recruiting | Primary Generalized Tonic-Clonic Seizures | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05667142) |
| November 14, 2022 | NCT05614063 | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures | Xenon Pharmaceuticals Inc. | Phase 3 | Completed | Focal Onset Seizures | 380 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05614063) |
| May 17, 2022 | NCT05376150 | A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder | Xenon Pharmaceuticals Inc. | Phase 2 | Completed | Major Depressive Disorder | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05376150) |
| July 7, 2021 | NCT04952467 | Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101 | Xenon Pharmaceuticals Inc. | Phase 1 | Completed | Healthy Volunteers | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04952467) |
| June 3, 2021 | NCT04912856 | An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE | Xenon Pharmaceuticals Inc. | Phase 3 | Terminated | Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous... | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04912856) |
| November 20, 2020 | NCT04639310 | XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy | Xenon Pharmaceuticals Inc. | Phase 3 | Terminated | Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous... | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04639310) |
| January 8, 2019 | NCT03796962 | A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy | Xenon Pharmaceuticals Inc. | Phase 2 | Active not recruiting | Focal Epilepsy | 325 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03796962) |
| March 16, 2018 | NCT03468725 | Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101 | Xenon Pharmaceuticals Inc. | Phase 1 | Completed | Healthy Male Volunteers | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03468725) |
| March 15, 2018 | NCT03467100 | Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901 | Xenon Pharmaceuticals Inc. | Phase 1 | Completed | Healthy Volunteers | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03467100) |
| November 13, 2017 | NCT03340220 | Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101. | Xenon Pharmaceuticals Inc. | Phase 1 | Completed | Healthy Volunteers | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03340220) |
| January 14, 2016 | NCT02656043 | A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel | Xenon Pharmaceuticals Inc. | Phase 1/2 | Completed | Acne Vulgaris | 213 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02656043) |
| December 6, 2011 | NCT01486446 | Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With... | Xenon Pharmaceuticals Inc. | Phase 1/2 | Completed | Primary Erythromelalgia, Inherited Erythromelalgia | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01486446) |
| September 6, 2010 | NCT01195636 | A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN) | Xenon Pharmaceuticals Inc. | Phase 2 | Completed | Postherpetic Neuralgia | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01195636) |
| March 22, 2010 | NCT01090622 | Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM) | Xenon Pharmaceuticals Inc. | Phase 1/2 | Completed | Primary Erythromelalgia, Inherited Erythromelalgia | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01090622) |
| August 7, 2009 | NCT00954356 | Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction | Xenon Pharmaceuticals Inc. | Phase 2 | Completed | Dental Pain | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00954356) |
| December 23, 2008 | NCT00813670 | Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers | Xenon Pharmaceuticals Inc. | Phase 1 | Completed | Healthy Human Volunteers | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00813670) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 1/2 | 3 |
| Phase 2 | 4 |
| Phase 3 | 11 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 12 |
| Active not recruiting | 5 |
| Terminated | 3 |
| Recruiting | 2 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Epilepsy | 7 |
| Seizures | 5 |
| Depressive Disorder, Major | 4 |
| Depression | 4 |
| Disease | 2 |
| Brain Diseases | 2 |
| Central Nervous System Diseases | 2 |
| Nervous System Diseases | 2 |
| Epileptic Syndromes | 2 |
| Bipolar Disorder | 2 |
| Epilepsies, Partial | 2 |
| Erythromelalgia | 2 |
| Neuralgia, Postherpetic | 1 |
| Peripheral Vascular Diseases | 1 |
| Vascular Diseases | 1 |
| Cardiovascular Diseases | 1 |
| Toothache | 1 |
| Acne Vulgaris | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Stone and masonry companies in the United States](https://specstream.ai/data/businesses/stone-and-masonry-companies/united-states)
- [Bangladeshi restaurants in the United States](https://specstream.ai/data/businesses/bangladeshi-restaurants/united-states)
- [Event technology companies in the United States](https://specstream.ai/data/businesses/event-technology-companies/united-states)
- [Medical billing companies in the United States](https://specstream.ai/data/businesses/medical-billing-companies/united-states)
- [Smoothie and juice bars in the United States](https://specstream.ai/data/businesses/smoothie-and-juice-bars/united-states)
